translocase of inner mitochondrial membrane 29Genealiases: C19orf52 · TIM29
Q-omics provides the consensus-scored TIMM29 profile across patient tissues and cancer cell-line models. TIMM29 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, TIMM29 is differentially expressed in 14, with the highest sampling consensus in COAD. Additionally, TIMM29 RNA expression shows 19,438 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight ACC, and COAD as cancer lineages where TIMM29 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TIMM29 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TIMM29 survival associations across molecular data types. TIMM29 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (1) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TIMM29 RNA expression–survival associations across cancer types. High TIMM29 expression shows unfavorable associations in ACC, KICH and LIHC, but favorable associations in STAD, CESC and HNSC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for TIMM29 RNA expression.
This table summarizes TIMM29 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 6. The strongest signals are observed in COAD for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for TIMM29. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TIMM29 shows higher tumor expression in COAD, HNSC, BLCA, LIHC, KIRP and LUAD. The COAD box plot shows higher TIMM29 RNA expression in tumor versus normal tissue (log2 FC = +0.770, t-test p < 0.001).
This table shows molecular features associated with TIMM29 in patient tissues and cancer cell lines. In patient samples, TIMM29 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, TIMM29 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in STOMACH, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and SOFT_TISSUE.
